Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31512910 | 0.91 | GPR84 (0.43) | PTPN1GPR84FFAR4FFAR1ALDH1A1 | |
| SCHEMBL19628780 | 0.83 | FFAR4 (0.50) | PTPN1GPR84FFAR4FFAR1NFKB1 | |
| SCHEMBL19628779 | 0.83 | FFAR4 (0.50) | PTPN1GPR84FFAR4FFAR1NFKB1 | |
| SCHEMBL19628781 | 0.83 | FFAR4 (0.50) | PTPN1GPR84FFAR4FFAR1NFKB1 | |
| SCHEMBL19628773 | 0.83 | FFAR4 (0.50) | PTPN1GPR84FFAR4FFAR1NFKB1 | |
| SCHEMBL10598029 | 0.82 | GPR84 (0.55) | GPR84FFAR4FFAR1NFKB1ACHE | |
| SCHEMBL11781608 | 0.82 | GPR84 (0.41) | PTPN1GPR84FFAR4FFAR1ALDH1A1 | |
| SCHEMBL27840946 | 0.80 | FFAR4 (0.47) | PTPN1GPR84FFAR4FFAR1ALDH1A1 | |
| SCHEMBL3337297 | 0.79 | PTPN1 (0.55) | PTPN1GPR84FFAR4FFAR1NFKB1 | |
| SCHEMBL27757278 | 0.79 | GPR84 (0.42) | PTPN1GPR84FFAR4FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008593-B2 | Process for producing 1,3-propanediol compound | Photanol, B.V. | 2021-05-18 | — | — | US | disclosed |
| US-20190345523-A1 | PROCESS OF PRODUCING AN ORGANIC COMPOUND AND AN INTERMEDIARY COMPOUND | UNIVERSITEIT VAN AMSTERDAM (NL) | 2019-11-14 | — | — | US | disclosed |
| US-20190177752-A1 | Process for Producing an Organic Compound | PHOTANOL BV. (NL) | 2019-06-13 | — | — | US | disclosed |
| US-10131924-B2 | Process for producing an organic compound and an intermediary compound | PHOTANOL B.V. (NL) | 2018-11-20 | — | — | US | disclosed |
| US-20160083756-A1 | PROCESS FOR PRODUCING AN ORGANIC COMPOUND | RENOLIT HEALTHCARE B.V. (NL) | 2016-03-24 | — | — | US | disclosed |
| US-9228210-B2 | Process for producing an organic compound | PHOTANOL B.V. (NL) | 2016-01-05 | — | — | US | disclosed |
| WO-2014092562-A1 | SYNTHESIS OF ACETOIN, 2,3-BUTANEDIOL AND 2-BUTANOL BY CYANOBACTERIA BY HETEROLOGOUS EXPRESSION OF A CATABOLIC PATHWAY | PHOTANOL B.V. (NL) | 2014-06-19 | — | — | WO | disclosed |
| US-20090221596-A1 | Substtituted aryl oximes | BAYER CROPSCIENCE AG (DE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221596-A1 | Substtituted aryl oximes | CYP1A1, PRDX1, CYP1A2 | PTPN1 566/4885GPR84 2660/4885FFAR4 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.